AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00644059 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine
Description: For both vaccines, either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.
Study NCT00644059 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
Description: 1. Meningococcal vaccine: two IM injections~2. Tick-borne encephalitis vaccine: two IM injections
Study NCT02101151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3(cholecalciferol)
Study NCT02101151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3(cholecalciferol)
Study NCT02020941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Given IV
Study NCT02020941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV or PO
Study NCT02020941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04260633 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Monitoring assisted aligner change, 12-hour tray wear time and VPro+ are the interventions for the trial.
Description: The current standard of care for clear aligner use as suggested by Invisalign is unclear as to how frequently aligners should be changed. We suspect that the frequency for aligner change as determined by the orthodontist using Dental Monitoring will be variable for every participant.~Vpro+ is an adjunctive therapeutic tool for clear aligner treatment. It is proposed to deliver high frequency vibrations to reduce treatment time and pain associated with clear aligners.~Align Technology suggests 22-hour wear time for clear aligner therapy. Participants in two arms of the study will be asked to wear the trays for about half the recommended wear time to assess whether night-time aligner wear will be sufficient for successful treatment.
Study NCT04260633 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Dental Monitoring assisted aligner change, 12-hour tray wear time and VPro+ are the interventions for the trial.
Description: The current standard of care for clear aligner use as suggested by Invisalign is unclear as to how frequently aligners should be changed. We suspect that the frequency for aligner change as determined by the orthodontist using Dental Monitoring will be variable for every participant.~Vpro+ is an adjunctive therapeutic tool for clear aligner treatment. It is proposed to deliver high frequency vibrations to reduce treatment time and pain associated with clear aligners.~Align Technology suggests 22-hour wear time for clear aligner therapy. Participants in two arms of the study will be asked to wear the trays for about half the recommended wear time to assess whether night-time aligner wear will be sufficient for successful treatment.
Study NCT01877798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: volume resuscitation, vasoactive drug
Study NCT03599960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: * Idarubicin 12mg/m2 IV at D1~* Methotrexate at D1 (24H infusion, alkaline hydration, leucovorin rescue):~  * Patients \<65y and albuminemia >35 g/l and CrCl (MDRD)>60 ml/min: 3000 mg/m²~ * Patients \<65y and albuminemia \<35 g/l and/or CrCl (MDRD) \<60 ml/min: 1000 mg/m² IV~ * Patients ≥65y and albuminemia >35 g/l and CrCl (MDRD) > 60 ml/min : 1000 mg/m²~ * Patients ≥ 65y and albuminemia \< 35 g/l and/or CrCl (MDRD) \< 60 ml/min : 500 mg/m²~* L-asparaginase (SPECTRILA) : 5000 units/m² IV at D2, 5, 8, 11 (switch to Erwinia asparaginase/Cirsantaspase 25 000 U/m² with the same drug regimen in case of hypersensitivity reactions or significant diminution of asparaginase activity)~* Dexamethasone 40mg PO or IV at D1-4 (dose diminution at 20 mg for Age ≥65y)
Study NCT00822848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: I.V., days 1-3 of each cycle. Epirubicin to be omitted during cycle 2 (concomitant chemoradiation)
Study NCT00822848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Over 90 minutes I.V., days 1-3 of each cycle. Administered with hydration and Mesna.
Study NCT00822848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: P.O. daily beginning 2 weeks before first chemotherapy cycle, held 1 week before and after surgery.
Study NCT00822848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Study NCT00822848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00822848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00822848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: Preoperative administration has been the preference at our institution.
Study NCT00822848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00822848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Surgery should be planned for 2-4 weeks after the initiation of chemotherapy for cycle 3.
Study NCT00822848 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: 28 Gy (350 centigray (cGy) x 8 fractions in 10 days) beginning at the start of cycle 2. \*Boost: postoperative boost of 12 Gy (200 cGy x 6 fractions) for patients with positive surgical margins only.
Study NCT03329989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: During 3 treatment visits 12 injections will be given per treatment area
Study NCT03558516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium group
Description: We will dilute magnesium 6 gram with 0.9% sodium chloride to 30 ml. The patient will receive magnesium sulfate 40 mg/kg infuse over 30 min started at skin incision and continuous drip 10 mg/kg/hr until the dura is closed. Anesthesia is standardized with propofol, fentanyl, cisatracurium and sevoflurane. Vasopressor or antihypertensive drug are used to control hemodynamics.
Study NCT03558516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline group
Description: The patient will receive 0.9% sodium chloride the same amount of magnesium sulphate infuse over 30 min started at skin incision and continuous drip until the dura is closed. Anesthesia is standardized with propofol, fentanyl, cisatracurium and sevoflurane. Vasopressor or antihypertensive drug are used to control hemodynamics.
Study NCT02431429 — intervention group
Intervention type: DRUG
Intervention: Miltefosine
Study NCT03424278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor control exercises
Description: Motor control exercises for the deep trunk muscles in patients with chronic low back pain is based on evidence of motor control dysfunction, including delayed onset of activity in the transversus abdomens and internal oblique abdominal muscles and segmental hypertrophy of the lumbar multifidus muscle.
Study NCT03424278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training exercises
Description: A type of strength-building exercise program that requires the body muscle to exert a force against some form of resistance, such as weight, stretch bands, water, or immovable objects. Resistance exercise is a combination of static and dynamic contractions involving shortening and lengthening of skeletal muscles.
Study NCT01492959 — intervention group
Intervention type: DRUG
Intervention: insulin human
Description: Insulin human delivered with the InnoLet® device was prescribed according to product labelling to subjects in need of insulin treatment
Study NCT00620906 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Manipulation
Description: HVLA manipulation to Sacroiliac Joint
Study NCT02054156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: 3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months
Study NCT02054156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months
Study NCT02054156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin solution for inhalation
Description: 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
Study NCT02054156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tobramycin solution for inhalation
Description: 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
Study NCT03130413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu Aura Gain supraglottic airway
Description: Anesthesia is induced with sevoflurane in oxygen. The anesthesia plane is gradually deepened by increasing the inspired concentration of sevoflurane (2-8%) till the loss of eyelash reflex. After intravenous (IV) cannula is inserted and intravenous fentanyl 1mcg/kg and rocuronium 0.6mg/kg are administered. Use of neuromuscular blocking agent is to minimize the risk of reflex activation of the airway. After 3 minutes, the appropriate size (depending upon body weight) of Ambu Aura Gain is lubricated with water soluble lubricant (KY jelly) is inserted by investigator based on manufacturer recommendation with the patient's head in neutral position. The cuff then is inflated to an intra-cuff pressure of 40 cm H20, measured using a digital cuff pressure monitor.
Study NCT03130413 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air-Q supraglottic airway
Description: Anesthesia is induced with sevoflurane in oxygen. The anesthesia plane is gradually deepened by increasing the inspired concentration of sevoflurane (2-8%) till the loss of eyelash reflex. After intravenous (IV) cannula is inserted and intravenous fentanyl 1mcg/kg and rocuronium 0.6mg/kg are administered. Use of neuromuscular blocking agent is to minimize the risk of reflex activation of the airway. After 3 minutes, the appropriate size (depending upon body weight) of Air-Q supraglottic airway is lubricated with water soluble lubricant (KY jelly) is inserted by investigator based on manufacturer recommendation with the patient's head in neutral position. The cuff then is inflated to an intra-cuff pressure of 40 cm H20, measured using a digital cuff pressure monitor.
Study NCT02330341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artemisia dracunculus
Study NCT02330341 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02914327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-5422 plus ibrutinib
Description: SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
Study NCT04120818 — intervention group
Intervention type: PROCEDURE
Intervention: secondary IOL implantation
Description: reopened the fibrotic, closed capsular bag and achieve IOL placement
Study NCT04120818 — intervention group
Intervention type: PROCEDURE
Intervention: primary IOL implantation
Description: lensectomy and anterior vitrectomy and primary IOL implantation
Study NCT00573924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proton pump inhibitor (lansoprazole)
Description: 1. 120 mg PO and then 30 mg PO q 3 h from 3 to 21 hrs~2. 90 mg IV bolus followed 9 mg/hr infusion for 24 hrs
Study NCT03715062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialogue tool
Description: The intervention has two parts: an educational session and a dialogue tool. The educational session consists of 75 minutes of education in diagnosing urinary tract infection. The dialogue tool consists of 1) a checking box for the most important symptoms and observations for urinary tract infection 2) an algorithm to evaluate if urinary tract infection is likely based on the present symptoms and observations 3) a list of reflection points to evaluate with a collegue 4) a specialized ISBAR (communication tool) if long-term care facility staff finds it appropriate to contact the General Practicioner
Study NCT03834350 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: BREATHES Program
Description: Participants will complete inhaler education using the virtual education module at the baseline visit of the study. Additionally, they will be asked to complete the lesson at least once before their 30 day follow-up visit on their personal device once they have been discharged from the hospital. At the time of their initial study visit, study participants will be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal. A small device will be attached to track real-time medication use.
Study NCT03834350 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BREATHES SpiroPD or Propeller Health
Description: At the time of their initial study visit, study participants may be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal. A small device will be attached to track real-time medication use.
Study NCT03188575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SilverCloud Internet-delivered Cognitive Behavioural Therapy
Description: SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions for all of the anxiety disorders (panic disorder, social anxiety, phobias, GAD, health anxiety, OCD), depression and also comorbid depression and anxiety. The programs for the treatment of depression and anxiety employ several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social. Research on the SilverCloud interventions has yielded significant clinical outcomes (Richards et al., 2015).
Study NCT03188575 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waiting List
Description: 8 week waiting list period.
Study NCT04069117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole 2.5mg (Femara; Novartis Pharma Services, Basel, Switzerland)
Description: letrozole /antagonist protocol
Study NCT03203785 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate (maltodextrin)
Description: maltodextrin flavored
Study NCT03203785 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-caloric drink
Study NCT01092377 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA and EPA Fish Oil capsule
Description: 2 DHA/EPA capsules on 4 days per week containing totally 420 mg DHA and 80 mg EPA, providing an average dose of 285.7 mg n-3 fatty acids per day
Study NCT01092377 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron tablet
Description: 1 iron tablet containing 50 mg of iron as ferrous sulfate will be administered on 4 days per week, providing an average iron dose of 28.6 mg iron per day.
Study NCT01092377 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Iron tablet
Description: 1 iron tablet containing 50 mg of iron as ferrous sulfate will be administered on 4 days per week, providing an average iron dose of 28.6 mg iron per day.
Study NCT01092377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Placebo tablet will be administered on 4 days per week and will be identical in appearance to the iron tablet.
Study NCT01092377 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet will be administered on 4 days per week and will be identical in appearance to the iron tablet.
Study NCT01092377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo capsules contain medium chain triglycerides and will be identical in appearance and total fat content to the DHA/EPA capsules.
Study NCT01092377 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsules contain medium chain triglycerides and will be identical in appearance and total fat content to the DHA/EPA capsules.
Study NCT03523286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RAPID-VT Software guided ablation
Description: Catheter ablation will target VT exit sites at scar margin as determined by the RAPID-VT software
Study NCT01603277 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-GM-CSF Monoclonal Antibody 400mg
Description: Anti-GM-CSF Monoclonal Antibody 400mg
Study NCT01603277 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study NCT01206764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Study NCT04228224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted training with a lower extremity powered exoskeleton (H3 Exoskeleton, Spain)
Description: The H3 is a powered lower extremity exoskeleton with actuated at hips, knees and ankles joints. A novel control software has been design and implemented in this device, which allows selective joint movement and recording of data from each rehabilitation session.
Study NCT04228224 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional gait rehabilitation
Description: Conventional gait rehabilitation consist in walking and other applicable lower limb exercises performed by participants with assistance of a physical therapist.
Study NCT04435496 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GYN-CS
Description: placement of the GYN-CS device
Study NCT00496561 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous immunotherapy (House Dust Mites)
Description: subcutaneous immunotherapy (House Dust Mites)
Study NCT00496561 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo of subcutaneous immunotherapy (House Dust Mites)
Description: placebo of subcutaneous immunotherapy (House Dust Mites)
Study NCT02506920 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Six different types of fat in a meal in random order
Description: Oral fat tolerance test
Study NCT02636621 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brazilian Dental Appliance
Description: Brazilian Dental Appliance is an oral appliance worn only during sleep that supports the jaw in a forward position to help maintain an open upper airway.
Study NCT02636621 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists in a protective dental plate worn only during sleep that do not interfere in the size of the upper airway.
Study NCT05912868 — intervention group
Intervention type: DEVICE
Intervention: Endoscopic Mini/Less Open Sublay Repair
Description: The traditional techniques are open sublay or transabdominal intraperitoneal onlay mesh (IPOM) repair. In order to avoid the risks -large trauma to the abdominal wall with pain and infection, lesion of intraabdominal organs - a new hybrid technique - small skin incision, wide endoscopic dissection of the retrorectus space with implantation of a large mesh - was developed (EMILOS -Endoscopic Mini/Less Open Sublay).
Study NCT01613924 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Split face: handheld acne heat based device (Zeno Hot Spot) and no treatment
Description: Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face at 6 hour intervals for a total of 3 treatments. Follow up will occur daily over a 5 day period.
Study NCT01613924 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Split face: handheld acne heat based device, Zeno Hot Spot, and topical benzoyl peroxide 4%
Description: Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face at 6 hour intervals for a total of 3 treatments. Subjects will apply benzoyl peroxide to the other half of the face daily for 5 days.
Study NCT01900444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMOJEV
Description: 0.5 mL, Subcutaneous
Study NCT01951716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Graded Glucose Infusion with Placebo
Description: Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes.
Study NCT01951716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Graded Glucose Infusion with GIP Alone
Description: Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of GIP in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes.